EX-16.1 2 ex_387346.htm EXHIBIT 16.1 HTML Editor

 

Exhibit 16.1

 

 

 

 

 

June 17, 2022

 

 

Securities and Exchange Commission

Washington, D.C. 20549

 

 

Commissioners:

 

 

We have read KemPharm, Inc’s statements included under Item 4.01(a) of its Form 8-K filed on June 17, 2022 and we agree with such statements concerning our firm.

 

 

/s/ RSM US LLP